pregnant women participating in a trial of maternal respiratory syncytial virus (RSV) vaccination

GSK halted its phase 3 vaccine trial on 28 February 2022 after a safety signal emerged: a possible increased risk of preterm births and neonatal deaths. In the vaccine arm, 6.81% of births were preterm (95% confidence interval 5.99% to 7.69%) compared with 4.95% (3.97% to 6.07%) in the placebo arm.

Nez, kāds atceras kādi bija cipari kovid vakcīnas testos uz grūtniecēm?

#grūti-atcerēties #izkrita-no-atmiņas #nevaru-atsaukt #anyway-droša-visām-grūtniecēm